SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

Trial Profile

SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Selumetinib (Primary) ; Vistusertib (Primary)
  • Indications Nerve sheath neoplasms; Neurofibromatoses
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Jul 2018.
    • 10 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top